De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Publication | Closed Access

DOI

162

Citations

References

2017

Year

Ulrike Nitz, Oleg Gluz, Matthias Christgen, E.‐M. Grischke, Doris Augustin, Sherko Küemmel, Michael Braun, Jochem Potenberg, A. Kohls, Katja Krauss,

Annals of Oncology

Breast OncologyMedicineNeoadjuvant Dual BlockadePharmacologyImmune Checkpoint InhibitorBreast CancerPharmacotherapyDe-escalation StrategiesCancer TreatmentOncologyFinal Analysis